Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Recruiting Phase 3 Interventional

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

NCT07444450
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Salanersen, Sham Procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
0 Days to 7 Months
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Flower Mound, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

NCT00555724
View directory record Official record
Conditions
Solid Tumors
Interventions
BIIB022
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

NCT02686268
View directory record Official record
Conditions
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • Amherst, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

NCT00288990
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

NCT07149415
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone, Omeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

NCT06264440
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122, Rabeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

NCT00493467
View directory record Official record
Conditions
Lymphoma
Interventions
Ibritumomab Tiuxetan (Zevalin), Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

NCT03385525
View directory record Official record
Conditions
Drug Interaction
Interventions
BIIB074, Valproic Acid
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 17, 2026, 11:34 AM EDT
Terminated Phase 1 Interventional

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

NCT00527410
View directory record Official record
Conditions
Leptomeningeal Carcinomatosis
Interventions
RTA 744
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 17, 2026, 11:34 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

NCT07219043
View directory record Official record
Conditions
Microvascular Inflammation
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 74 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

NCT02611674
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
16 Years to 85 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 17, 2026, 11:34 AM EDT
Recruiting No phase listed Observational

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

NCT07398469
View directory record Official record
Conditions
Postpartum Depression
Interventions
Zuranolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

NCT03507686
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

NCT00031083
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions
Interferon-beta
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 17, 2026, 11:34 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
29
States / cities
Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 11:34 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

NCT01797965
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB019 (Daclizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 17, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

NCT02283918
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 58 Years
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Thornton, Colorado • Decatur, Georgia • Latham, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

NCT03116113
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIIB112
Biological
Lead sponsor
Biogen
Industry
Eligibility
10 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 17, 2026, 11:34 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 11:34 AM EDT
Completed No phase listed Observational

Tecfidera Lymphocyte Chart Review

NCT02519413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 17, 2026, 11:34 AM EDT
Completed Phase 3 Interventional Results available

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
ALKS 8700, Dimethyl Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 17, 2026, 11:34 AM EDT